Acquisition - March 10, 2021
Amgen to acquire Five Prime Therapeutics for USD 1.9 billion
Amgen and Five Prime Therapeutics have announced an agreement under which Amgen will acquire Five Prime Therapeutics for USD 38 per share in cash, representing an equity value of approximately USD 1.9 billion. Five Prime’s lead asset, bemarituzumab, is a Phase 3 ready anti-FGFR2b antibody with positive data from a randomized, placebo-controlled Phase 2 study […]
In a new job - February 10, 2021
Amgen Sweden appoints new Medical Director
Sandra Eketorp Sylvan has been appointed Medical Director Sweden at Amgen. Eketorp Sylvan is a medical doctor, specialist in oncology, and she has experience from organization development and digitalization within the healthcare sector, according to Amgen. “With her broad clinical experience and deep knowledge within translational research, which she still conducts actively, Sandra Eketorp Sylvan […]
Acquisition - May 24, 2019
Amgen to buy Nuevolution for $166.8 million
Amgen has agreed to buy the biopharmaceutical company Nuevolution AB for 1.61 billion Swedish crowns ($166.8 million) to boost its position in drug discovery. Nuevolution said its board unanimously recommended Amgen’s cash offer of 32.5 Swedish crowns per share, a premium of 168.6% to Nuevolution’s closing price on Tuesday, reported Reuters. The offer from Amgen […]
Collaboration - May 27, 2015
Amgen, AZ End Psoriasis Drug Deal
Amgen is dissolving an agreement with AstraZeneca to develop the psoriasis drug brodalumab after a patient involved in a late-stage trial developed suicidal thoughts and behavior, according to BioSpace.com. Because of that incident, if the drug were eventually approved by regulators, they would likely require restrictive labeling, which discouraged Amgen. The latest news came as […]
Collaboration - April 24, 2015
AZ, Amgen Switch to Psoriasis
Amgen and partner AstraZeneca are preparing to deliver U.S. and European applications for their plaque psoriasis drug brodalumab by midyear. The two companies halted tests for brodalumab as an asthma medication. Amgen outlined the news in its quarterly report, which also notes a 14 percent drop in R&D spending. “Based on the recommendation of an […]
Clinical Trials - May 12, 2014
Amgen and AstraZeneca announce positive results from psoriasis study
The two companies have announced positive results from Phase III study of brodalumab (AMG 827) in patients with moderate-to-severe plaque psoriasis. According to AstraZeneca, the study evaluating brodalumab in patients with moderate-to-severe plaque psoriasis met all primary and secondary endpoints for both evaluated doses. Primary endpoints were patients achieving at least a 75 percent improvement from baseline […]
